Avantor, Inc. (AVTR) Gross Margin
- Gross margin · 12 months: Value 32.13%; Formula and calculation Gross profit / revenue. Period ending 2026-03-31..
Gross margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 32.13% | Gross profit / revenue. Period ending 2026-03-31. $2.11B ÷ $6.55B × 100 ≈ 32.13% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 2.11B USD | Gross Profit |
| Revenue | 6.55B USD | |
| Cost of products and services | 4.45B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-03-31 | $2.11B | $6.55B | $4.45B | 32.13% |
| 2025-12-31 | $2.14B | $6.55B | $4.41B | 32.65% |
| 2025-09-30 | $2.18B | $6.58B | $4.40B | 33.13% |
| 2025-06-30 | $2.22B | $6.67B | $4.45B | 33.25% |
| 2025-03-31 | $2.24B | $6.69B | $4.44B | 33.56% |
| 2024-12-31 | $2.28B | $6.78B | $4.50B | 33.60% |
| 2024-09-30 | $2.29B | $6.82B | $4.53B | 33.53% |
| 2024-06-30 | $2.30B | $6.83B | $4.52B | 33.71% |
| 2024-03-31 | $2.31B | $6.87B | $4.56B | 33.63% |
| 2023-12-31 | $2.36B | $6.97B | $4.60B | 33.93% |
| 2023-09-30 | $2.41B | $7.04B | $4.63B | 34.21% |
| 2023-06-30 | $2.48B | $7.18B | $4.70B | 34.56% |
| 2023-03-31 | $2.54B | $7.34B | $4.80B | 34.56% |
| 2022-12-31 | $2.60B | $7.51B | $4.91B | 34.65% |
| 2022-09-30 | $2.64B | $7.63B | $4.99B | 34.57% |
| 2022-06-30 | $2.60B | $7.60B | $5.00B | 34.21% |
| 2022-03-31 | $2.58B | $7.55B | $4.97B | 34.17% |
| 2021-12-31 | $2.50B | $7.39B | $4.88B | 33.88% |
| 2021-09-30 | $2.44B | $7.27B | $4.83B | 33.52% |
| 2021-06-30 | $2.33B | $7.04B | $4.71B | 33.06% |
| 2021-03-31 | $2.19B | $6.66B | $4.47B | 32.90% |
| 2020-12-31 | $2.08B | $6.39B | $4.31B | 32.54% |
| 2020-09-30 | $1.98B | $6.13B | $4.15B | 32.31% |
| 2020-06-30 | $1.95B | $6.03B | $4.08B | 32.31% |
| 2020-03-31 | $1.95B | $6.08B | $4.13B | 32.03% |
| 2019-12-31 | $1.92B | $6.04B | $4.12B | 31.80% |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | $1.85B | $5.93B | (m) | 31.30% |
| 2018-12-31 | $1.82B | $5.86B | $4.04B | 31.03% |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | $432.80M | $1.25B | $814.60M | 34.70% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |